Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children.

Research paper by Natalia N Maximova, D D Zanon, F F Rovere, A A Maestro, G G Schillani, R R Paparazzo

Indexed on: 19 Jun '15Published on: 19 Jun '15Published in: International Journal of Hematology


The outcome of romiplostim for secondary failure of platelet recovery (SFPR) was investigated in children who had undergone hematopoietic stem cell transplantation (HSCT). Seven transfusion-dependent pediatric patients (median age 11 years), with platelet counts below 10 × 10(9)/L, received four weekly doses of subcutaneous romiplostim to treat SFPR developed after HSCT. All patients, except one (patient 4), became platelet transfusion-independent in the second week from the beginning of treatment and no patient needed to discontinue drug treatment because of adverse events. Romiplostim could represent a beneficial first-line treatment, but further studies are required.